Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Iovance Biotherapeutics Ownership Summary


Iovance Biotherapeutics is owned by 32.99% institutional investors, 1.10% insiders, and 65.92% retail investors. Vanguard group is the largest institutional shareholder, holding 9.08% of IOVA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIovance Biotherapeutics32.99%1.10%65.92%
SectorHealthcare Stocks 57.43%9.41%33.16%
IndustryBiotech Stocks 69.02%8.92%22.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group27.53M9.08%$203.75M
Mhr fund management24.42M8.05%$180.69M
Blackrock21.23M7.97%$170.23M
Blackrock funding, inc. /de23.48M7.74%$173.72M
Perceptive advisors22.11M7.29%$163.63M
State street12.63M4.74%$101.25M
Hood river capital management8.99M2.96%$66.54M
Soleus capital management6.56M2.16%$48.54M
Geode capital management5.87M1.94%$43.46M
T. rowe price investment management5.83M1.92%$43.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mhr fund management24.42M19.98%$180.69M
Apis capital advisors1.36M6.72%$10.09M
Perceptive advisors22.11M4.51%$163.63M
Palo alto investors lp3.04M3.49%$22.51M
Orion investment1.06M3.13%$7.85M
Soleus capital management6.56M3.05%$48.54M
Bioimpact capital2.67M2.81%$19.79M
Parametrica management261.09K2.55%$1.93M
Cm management300.00K1.98%$2.22M
Stempoint capital lp949.40K1.75%$7.03M

Top Buyers

HolderShares% AssetsChange
Man group2.41M0.05%2.41M
State street12.63M0.00%2.22M
Ubs group2.70M0.00%2.08M
Blackrock funding, inc. /de23.48M0.00%1.99M
Assenagon asset management1.75M0.02%1.75M

Top Sellers

HolderShares% AssetsChange
Perceptive advisors22.11M4.51%-4.51M
Soleus capital management6.56M3.05%-1.97M
Balyasny asset management2.82M0.03%-1.65M
Summit partners public asset management---1.56M
Opaleye management---897.00K

New Positions

HolderShares% AssetsChangeValue
Man group2.41M0.05%2.41M$17.87M
Assenagon asset management1.75M0.02%1.75M$12.93M
Raymond james financial1.56M0.00%1.56M$11.57M
Artal group1.01M0.21%1.01M$8.11M
Stempoint capital lp949.40K1.75%949.40K$7.03M

Sold Out

HolderChange
Capital performance advisors llp-11.00
Massmutual trust co fsb/adv-28.00
Cibc private wealth group-35.00
Nelson, van denburg & campbell wealth management group-46.00
Fifth third bancorp-62.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024193-35.02%100,034,590-57.33%320.55%92-39.07%50-37.50%
Sep 30, 2024292-5.19%234,393,8080.82%771.01%149-17.22%80-2.44%
Jun 30, 20243052.69%232,471,4507.59%871.23%1779.94%82-6.82%
Mar 31, 202429718.33%216,063,2144.25%841.19%16113.38%8831.34%
Dec 31, 20232511.21%207,248,234-2.24%840.95%142-2.74%6721.82%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv8.64M2.83%25.89K
Vanguard Small Cap Index7.00M2.30%12.47K
iShares Russell 2000 ETF7.15M2.18%-139.85K
SPDR® S&P Biotech ETF5.94M1.81%44.80K
Hood River Small-Cap Growth Instl5.10M1.67%525.69K
Vanguard Small Cap Value Index Inv4.63M1.52%-8.69K
Macquarie Small Cap Core I3.91M1.28%969.77K
Vanguard Institutional Extnd Mkt Idx Tr3.45M1.13%976.00
Delaware Small Cap Core I2.61M0.86%1.84M
Fidelity Small Cap Index2.57M0.84%-17.09K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 12, 2024Maynard Ryan D-Sell$503.00K
Feb 20, 2024MCPEAK MERRILL A-Buy$2.29M
Feb 20, 2024Dukes Iain D.-Buy$292.80K
Feb 20, 2024Rothbaum Wayne P.-Buy$45.75M
Sep 18, 2023MCPEAK MERRILL A-Buy$55.60K

Insider Transactions Trends


DateBuySell
2025 Q1--
2024 Q4-1
2024 Q3--
2024 Q2--
2024 Q13-

IOVA Ownership FAQ


Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 32.99%, followed by 1.10% insiders and 65.91% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 69.02%, which Iovance Biotherapeutics falls below.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Vanguard group (27.53M shares, 9.08%), Mhr fund management (24.42M shares, 8.05%), and Blackrock (21.23M shares, 7.97%). Together, they hold 25.10% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Mhr fund management is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 19.98% of its assets in 24.42M Iovance Biotherapeutics shares, valued at 180.69M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Iovance Biotherapeutics shares, with 2.83% of its total shares outstanding invested in 8.64M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools